140 related articles for article (PubMed ID: 21155760)
1. Allogeneic transplantation for Hodgkin's lymphoma.
Corradini P; Sarina B; Farina L
Br J Haematol; 2011 Feb; 152(3):261-72. PubMed ID: 21155760
[TBL] [Abstract][Full Text] [Related]
2. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Sureda A; Robinson S; Canals C; Carella AM; Boogaerts MA; Caballero D; Hunter AE; Kanz L; Slavin S; Cornelissen JJ; Gramatzki M; Niederwieser D; Russell NH; Schmitz N
J Clin Oncol; 2008 Jan; 26(3):455-62. PubMed ID: 18086796
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
4. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
5. Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation.
Cook G; Smith GM; Kirkland K; Lee J; Pearce R; Thomson K; Morris E; Orchard K; Rule S; Russell N; Craddock C; Marks DI;
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1419-27. PubMed ID: 20399879
[TBL] [Abstract][Full Text] [Related]
6. 'GVHD': graft-versus-host disease or graft-versus-Hodgkin's disease? An old acronym with new meaning.
Porter DL; Stadtmauer EA; Lazarus HM
Bone Marrow Transplant; 2003 May; 31(9):739-46. PubMed ID: 12732878
[TBL] [Abstract][Full Text] [Related]
7. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
8. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion.
Todisco E; Castagna L; Sarina B; Mazza R; Anastasia A; Balzarotti M; Banna G; Tirelli U; Soligo D; Santoro A
Eur J Haematol; 2007 Apr; 78(4):322-9. PubMed ID: 17253967
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol.
Alvarez I; Sureda A; Caballero MD; Urbano-Ispizua A; Ribera JM; Canales M; García-Conde J; Sanz G; Arranz R; Bernal MT; de la Serna J; Díez JL; Moraleda JM; Rubió-Félix D; Xicoy B; Martínez C; Mateos MV; Sierra J
Biol Blood Marrow Transplant; 2006 Feb; 12(2):172-83. PubMed ID: 16443515
[TBL] [Abstract][Full Text] [Related]
11. Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma.
Sureda A
Hematol Oncol Clin North Am; 2007 Oct; 21(5):943-60. PubMed ID: 17908630
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic transplantation for Hodgkin lymphoma.
Peggs KS; Anderlini P; Sureda A
Br J Haematol; 2008 Nov; 143(4):468-80. PubMed ID: 18710379
[TBL] [Abstract][Full Text] [Related]
13. Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma.
Claviez A; Sureda A; Schmitz N
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S16-24. PubMed ID: 18978738
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation.
Thomson KJ; Peggs KS; Smith P; Cavet J; Hunter A; Parker A; Pettengell R; Milligan D; Morris EC; Goldstone AH; Linch DC; Mackinnon S
Bone Marrow Transplant; 2008 May; 41(9):765-70. PubMed ID: 18195684
[TBL] [Abstract][Full Text] [Related]
17. Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas.
Bishop MR; Hou JW; Wilson WH; Steinberg SM; Odom J; Castro K; Kasten-Sportes C; Gea-Banacloche J; Marchigiani D; Gress R; Fowler DH
Biol Blood Marrow Transplant; 2003 Mar; 9(3):162-9. PubMed ID: 12652466
[TBL] [Abstract][Full Text] [Related]
18. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed Hodgkin's disease following autologous stem cell transplantation.
Ruiz-Argüelles GJ; López-Martínez B; López-Ariza B
Arch Med Res; 2003; 34(3):242-5. PubMed ID: 14567405
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease.
Hale GA; Phillips GL
Cancer Treat Rev; 2000 Dec; 26(6):411-27. PubMed ID: 11139372
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic transplantation in lymphoma: current status.
Schmitz N; Dreger P; Glass B; Sureda A
Haematologica; 2007 Nov; 92(11):1533-48. PubMed ID: 18024402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]